Nakasone Tadaharu, Nakamoto Tomoko, Matsuzaki Akiko, Nakagami Hiroshige, Aoki Yoichi
Department of Obstetrics and Gynecology, Graduate School of Medicine, University of the Ryukyus, Japan.
Department of Obstetrics and Gynecology, Okinawa Prefectual Yaeyama Hospital, Japan.
Gynecol Oncol Rep. 2019 Jul 16;29:73-75. doi: 10.1016/j.gore.2019.07.006. eCollection 2019 Aug.
Steroid cell tumor (SCT) not otherwise specified (NOS) is rare and recurrence and metastasis rarely occurs; therefore, reports regarding its treatment are limited. We report a case of recurrent SCT-NOS treated with gonadotropin releasing hormone agonist (GnRHa) and successful.
A 50-year-old woman underwent a staging laparotomy and diagnosed as SCT-NOS. Multiple liver tumors and intraperitoneal dissemination were detected 5 years 10 months after the initial surgery. As the immunohistochemical analysis showed positive staining for GnRH receptor, GnRHa was attempted. After the first cycle the serum testosterone level was normalized and after six cycles CT scan confirmed reduction of the tumor size.
Some ovarian SCT-NOS have GnRH receptors; thus, GnRHa may have a reducing effect for these tumors without major adverse event.
未另行指定的类固醇细胞瘤（SCT）较为罕见，复发和转移很少发生；因此，关于其治疗的报道有限。我们报告一例用促性腺激素释放激素激动剂（GnRHa）治疗成功的复发性未另行指定的SCT病例。
一名50岁女性接受了分期剖腹手术，被诊断为未另行指定的SCT。初次手术后5年10个月检测到多发肝肿瘤和腹膜内播散。由于免疫组化分析显示促性腺激素释放激素（GnRH）受体染色阳性，遂尝试使用GnRHa。第一个周期后血清睾酮水平恢复正常，六个周期后CT扫描证实肿瘤大小缩小。
一些卵巢未另行指定的SCT有GnRH受体；因此，GnRHa可能对这些肿瘤有缩小作用且无重大不良事件。
Zotero 插件
